Background
Methods
Population Collection & Phenotype
Polymorphisms selection and Genotyping
GRIA1
GRIA2
GRIA3
GRIA4
GENE | SNP | PRIMERS | MT | SIZE | ENZYME | ALLELE 1 (size) | ALLELE 2 (size) |
---|---|---|---|---|---|---|---|
GRIA1 | rs548294 | AGATGAAGAAACAGAGGTC | 56°C | 311 bp | MwoI | C (123/188) | T (311) |
CCCCAGGTACTATTCAAAG | |||||||
GRIA1 | rs2195450 | TCTAAGAGGAGGGGGCAAGG | 60°C | 367 bp | TaqI | G (218/149) | A (367) |
GCTTGGTAGATGGTGCTTGA | |||||||
GRIA3 | rs3761555 | CTGGAACAATGGAACAAAAT | 55°C | 272 bp | BglII | T (272) | C (111/161) |
ATAATGCTATGTCCCTGTCT |
Association Analysis
Electrophoretic mobility shift assays
Luciferase assays
Ethical approval
Results
GRIA1 and GRIA3genes are associated with migraine
Gene | SNP | SAMPLE
| N | MAF | SP | MAJOR HOMO
| HET
| MINOR HOMO
| ALLELE P-VALUE
| 11 vs 12 | GENOTYPE P-VALUEs 11 vs 22 | 11 vs 12+22 | ARMITAGE'S TEST -P VALUE
|
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GRIA1
|
RS548294 C/T | CONTROLS
| 260 | 34% | 125 (48,1%) | 102 (39,2%) | 33 (12,7%) | ||||||
CONT.FEMALE
| 204 | 32,3% | 98 (48%) | 80 (39,2%) | 26 (12,8%) | ||||||||
CONT. MALE
| 56 | 32,1% | 27 (48,2%) | 22 (39,3%) | 7 (12,5%) | ||||||||
MIGRAINE ALL
| 244 | 44,3% | 97% | 80 (32,8%) | 112 (45,9%) | 52 (21,3%) |
0,00009 (0,002*)
(OR 1,7/CI 1,2-2,1) |
0,006 (NS*) (OR 1,7/CI 1,1-2,5) |
0,0005 (0,01*)
(OR 2,4/CI 1,5-4,1) |
0,0005 (0,01*)
(OR 1,9/CI 1,3-2,7) |
0,0002 (0,005*)
| ||
MA | 135 | 42,6% | 80% | 52 (38,5%) | 51 (37,8%) | 32 (23,7%) |
0,004 (NS*) (OR 1,6/CI 1,1-2,1) | 0,4 (NS*) |
0,004 (NS*) (OR 2,3/CI 1,3-4,1) | 0,07 (NS*) |
0,007 (NS*) | ||
MO | 109 | 46,3% | 78% | 28 (25,7%) | 61 (56%) | 20 (18,3%) |
0,0003 (0,008*)
(OR 1,8/CI 1,3-2,5) |
0,0001 (0,003*)
(OR 2,6/CI 1,6-4,5) |
0,003 (NS*) (OR 2,7/CI 1,3-5,3) |
0,00007 (0,002*) (OR 2,7/CI 1,6-4,3) | 0,0004 (0,01*) | ||
MIG. FEMALE
| 188 | 44,1% | 90% | 63 (33,5%) | 84 (44,7%) | 41 (21,5%) |
0,0007 (0,02*)
(OR 1,6/CI 1,2-2,2) |
0,02 (NS*) (OR 1,6/CI 1,0-2,5) |
0,002 (0,05*)
(OR 2,4/CI 1,3-4,4) |
0,003 (NS*) (OR 1,8/CI 1,2-2,7) |
0,001 (0,03*)
| ||
MIG. MALE
| 56 | 41% | 38% | 19 (34%) | 28 (50%) | 9 (16%) | 0,1 | 0,1 | 0,3 | 0,1 | 0,1 | ||
RS2195450 G/A | CONTROLS
| 260 | 34,2% | 128 (49,2%) | 86 (33%) | 46 (17,8%) | |||||||
CONT. FEMALE
| 204 | 34,5% | 95 (46,6%) | 77 (37,7%) | 32 (15,7%) | ||||||||
CONT. MALE
| 56 | 33% | 30 (53,6%) | 15 (26,7%) | 11 (19,6%) | ||||||||
MIGRAINE ALL
| 244 | 45,5% | 97% | 98 (40,1%) | 70 (28,7%) | 76 (31,2%) |
0,0002 (0,005*)
(OR 1,6/CI 1,2-2,0) | 0,7 |
0,0007 (0,02*)
(OR 2,1/CI 1,3-3,3) |
0,04 (NS*) (OR 1,4/CI 1-2) |
0,001 (0,03*)
| ||
MA | 135 | 50% | 80% | 51 (38%) | 33 (24%) | 51 (38%) |
0,00002 (0,0005*)
(OR 1,9/CI 1,4-2,5) | 0,8 |
0,00008 (0,002*)
(OR 2,7/CI 1,6-4,6) |
0,03 (NS*) (OR 1,6/CI 1,0-2,4) |
0,0002 (0,005*)
| ||
MO | 109 | 39% | 78% | 47 (43,2%) | 39 (35,7%) | 23 (21,1%) | 0,2 | 0,4 | 0,3 | 0,2 | 0,2 | ||
MIG. FEMALE
| 188 | 42,3% | 90% | 83 (44,1%) | 51 (27,1%) | 54 (28,8%) |
0,02 (NS*) (OR 1,3/CI 1-1,8) | 0,2 |
0,01 (NS*) (OR 1,9/CI 1,1-3,2) | 0,6 |
0,05 (NS*) | ||
MIG. MALE
| 56 | 53,5% | 38% | 17 (30,3%) | 18 (32,1%) | 21 (37,5%) |
0,001 (0,03*)
(OR 2,3/CI 1,3-4) | 0,1 |
0,01 (NS*) (OR 3,3/CI 1,3-8,6) |
0,01 (NS*) (OR 2,6/CI 1,2-5,7) |
0,008 (NS*) | ||
GRIA3
|
RS3761555 T/C | CONTROLS
| 260 | 22,3% | 170 (65,3%) | 64 (24,6%) | 26 (10,1%) | ||||||
CONT.FEMALE
| 204 | 23,5% | 124 (60,7%) | 64 (31,3%) | 16 (8%) | ||||||||
CONT. MALE
| 56 | 17,9% | 46 (82,1%) | 10 (17,9%) | |||||||||
MIG. FEM.ALL
| 188 | 34,6% | 93% | 83 (44,1%) | 80 (42,5%) | 25 (13,4%) |
0,0006 (0,01*)
(OR 1,7/CI 1,2-2,3) |
0,004 (NS*)
(OR 1,8/CI 1,2-2,8) |
0,01 (NS*)
(OR 2,3/CI 1,1-4,6) |
0,0009 (0,02*)
(OR 1,9/CI 1,3-2,9) |
0,001 (0,003*)
| ||
MA-FEMALE
| 112 | 38% | 84% | 44 (39,3%) | 51 (45,5%) | 17 (15,2%) |
0,0001 (0,003*)
(OR 2/CI 1,4-2,8) |
0,001 (0,03*) (OR 2,3/CI 1,3-3,7) |
0,003 (NS*)
(OR 3/CI 1,4-6,4) |
0,0002 (0,005*)
(OR 2,4/CI 1,5-3,8) |
0,0002 (0,005*)
| ||
MO-FEMALE
| 76 | 30% | 73% | 38 (50%) | 30 (39,5%) | 8 (10,5%) | 0,1 | 0,1 | 0,2 | 0,1 | 0,1 | ||
MIG. MALE
| 56 | 40% | 36 (64,5%) | 20 (35,5%) |
0,03 (NS*) (OR 2,46/CI 1,07-5,6) |
HAPLOTYPE
| CASES N = 452 | PERCENTAGE
| CONTROLS N = 504 | PERCENTAGE
| P-VALUE
| ODDS RATIO
| 95% CONFIDENCE INTERVAL
|
---|---|---|---|---|---|---|---|
C__A | 149 | 33% | 131 | 26% | 0.0180 | 1.40 | 1.06-1.85 |
C__G | 99 | 22% | 207 | 41% | 0.00001 | 0.40 | 0.30-0.54 |
T__A | 59 | 13% | 35 | 7% | 0.0015 | 2.10 | 1.30-3.12 |
T__G | 145 | 32% | 131 | 26% | 0.0381 | 1.34 | 1.02-1.78 |
C ONTROLS N = 260 | CASES N = 244 |
P-VALUE
|
OR
|
95% CI
| |
---|---|---|---|---|---|
TWO RISK ALLELES
| 6+3+31+9 (19%) | 24+6+29+22 (33%) | 0.00001 | 3.35 | 1.96-5.74 |
ONE RISK ALLELE (GRIA1) | 26+74 (39%) | 20+63 (34%) | 0.03 | 1.68 | 1.02-2.77 |
ONE RISK ALLELE (GRIA3) | 26+14 (15%) | 27+18 (19%) | 0.005 | 2.28 | 1.27-4.11 |
NO RISK ALLELE
| 71 (27%) | 35 (14%) |